Please enable Javascript
Peter Voorhees, MD
Peter Voorhees, MD, is from the Levine Cancer Institute.
Articles by Peter Voorhees, MD
Panel Discusses Best Practices for Post-CAR-T Management with Local Health Care Teams
Thomas Martin, MD
Video Insights
|
May 15, 2023
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
View More
Management of CAR-T Toxicities: CRS, Neurological, Cytopenias, Infection
Thomas Martin, MD
Video Insights
|
May 2, 2023
The panel discusses side effect management with CAR T-cell therapy.
View More
Bispecific Versus CAR T-Cell Therapy for Myeloma, Bridging Therapy Needs for CAR-T
Thomas Martin, MD
Video Insights
|
May 25, 2023
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
View More
Who Is the Right Patient for CAR-T Therapy?
Thomas Martin, MD
Video Insights
|
May 3, 2023
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
View More
Frontline CAR-T Use and the 'Sweet Spot' for Treatment Sequencing
Thomas Martin, MD
Video Insights
|
May 5, 2023
The panel addresses the potential for frontline CAR-T use.
View More
Moving CAR-T Therapy Earlier in the Myeloma Treatment Course
Thomas Martin, MD
Video Insights
|
May 3, 2023
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
View More
Is There an Ideal Space for Allogeneic CAR-T Products for Myeloma?
Thomas Martin, MD
Video Insights
|
May 4, 2023
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
View More
Dual-Targeting, Allogeneic CARs Are Options to ‘Keep Myeloma on its Toes’
Thomas Martin, MD
Video Insights
|
May 5, 2023
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
View More
A Look at the CAR-T Pipeline: ddBCMA and LUMMICAR
Thomas Martin, MD
Video Insights
|
May 4, 2023
BCMA-targeted autologous CAR T-cell therapies are discussed.
View More
Ciltacabtagene Autoleucel and CARTITUDE Findings in Relapsed/Refractory Myeloma
Thomas Martin, MD
Video Insights
|
May 4, 2023
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
View More
Idecabtagene Vicleucel for Myeloma: KarMMa Study Results and Real-World Evidence
Thomas Martin, MD
Video Insights
|
May 5, 2023
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
View More
Spotlight on BCMA: A Major Target for Multiple Myeloma
Thomas Martin, MD
Video Insights
|
May 5, 2023
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.
View More